WESTMINSTER, Colo., April 26 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced that Dr. Jeffrey R.
Latts, former Executive Vice President and Chief Medical Officer of
Exelixis, Inc., has been appointed to the Company's Board of Directors.
"We are delighted to welcome Jeff to our Board of Directors," said Paul
L. Berns, President and CEO of Allos. "Jeff brings to the Board over 25
years of experience in pharmaceutical development. We believe his
experience advancing programs from research into development and through
clinical testing will be important as we continue to grow and seek to
expand our clinical development efforts."
Dr. Latts has been a consultant to the pharmaceutical industry since
January 2007. Previously, Dr. Latts served as Executive Vice President of
Exelixis, Inc., a biotechnology company, from January 2006 to January 2007,
and as Senior Vice President of Exelixis, Inc. from July 2001 to December
2005. He also served as Chief Medical Officer of Exelixis, Inc. from July
2001 to September 2006. Prior to that, Dr. Latts held key management
positions with Berlex Laboratories, a pharmaceutical healthcare company,
where he served as Chief Medical Officer from 1995 to 2001, and Vice
President, Clinical Research and Development from 1990 to 2001. Prior to
that, Dr. Latts served as Vice President of Clinical Research at Wyeth
Ayerst Research, a division of Wyeth Laboratories. He began his career in
the pharmaceutical industry with the Parke-Davis Pharmaceutical Division of
Warner Lambert. In over 25 years in the pharmaceutical industry, Dr. Latts
has been involved in numerous investigational new drug application
submissions and has successfully initiated early to late stage clinical
trials for multiple disease areas, including cancer, immunology, central
nervous system and metabolic diseases. Dr. Latts received a B.S. in
medicine and an M.D. from the University of Minnesota.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The Company has two product candidates in
late-stage clinical development: EFAPROXYN (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in women
with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel antifolate currently under evaluation in a pivotal
Phase 2 trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The Company is also evaluating RH1, a targeted chemotherapeutic
agent, in a Phase 1 trial in patients with advanced solid tumors. For
additional information, please visit the Company's website at
http://www.allos.com.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Senior Manager, Corporate
Communications, +1-720-540-5227, jneiman@allos.com, or Derek
Cole, Vice President, Investor Relations, +1-720-540-5367,
dcole@allos.com, both of Allos Therapeutics, Inc.
|
